What is TG Therapeutics, Inc.'s earnings per share (EPS)?

TG Therapeutics, Inc. (TGTX) reported diluted earnings per share of $2.77 for fiscal year 2025. This represents a 1746.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

TG Therapeutics, Inc. (TGTX) Financials

TGTX

Trailing 12 months to June 30, 2026

Revenue $799.5M +76.1% YoY

Net Income $441.5M +630.1% YoY

EPS (Diluted) $2.75 +643.2% YoY

Free Cash Flow $17.4M +129.3% YoY

Market Cap $8.5B as of Oct 10, 2026

Price / Sales 10.6x on $799.5M revenue, trailing 12 months to June 30, 2026

Price / Earnings 19.2x on $441.5M net income, trailing 12 months to June 30, 2026

Price / Book 14.0x on $604.1M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 5, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TGTX SEC filings page.

TG Therapeutics, Inc. (TGTX) reported $799.5M in revenue over the twelve months to Jun 30, 2026, up 76.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TGTX FY2025 2026-10-03

Operating profitability arrived, but FY2025 reported earnings were dominated by a tax benefit while cash generation remained negative.

Operating margin widened over the last three reported years as revenue scaled, but operating cash flow remained negative in FY2025. The disconnect is tied to working capital: receivables and inventory together reached $431.2M in FY2025, while net income included a $339.8M tax benefit.

Gross margin compressed over the period even as operating margin expanded, indicating that scale and operating-cost absorption—rather than a richer gross-profit mix—drove the improvement. The business became profitable at the operating level without preserving its earlier gross-margin profile.

The balance sheet became larger and less debt-dependent: FY2025 total assets were $1.1B and debt-to-equity fell to 0.4x. Reported liquidity equaled 97.4 months of FY2025 operating outflow, yet free cash flow was negative at $25.0M; financing capacity and cash conversion therefore describe different aspects of the business.

Financial Health Signals

Financial Health Score 60/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of TG Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

TG Therapeutics, Inc. has an operating margin of 20.0%, meaning the company retains $20 of operating profit per $100 of revenue. This results in a moderate score of 64/100, indicating healthy but not exceptional operating efficiency. This is up from 12.7% the prior year.

Growth

TG Therapeutics, Inc.'s revenue surged 87.3% year-over-year to $616.3M, reflecting rapid business expansion. This strong growth earns a score of 96/100.

Leverage

TG Therapeutics, Inc. has a moderate D/E ratio of 0.38. This balance of debt and equity financing earns a leverage score of 41/100.

Liquidity

With a current ratio of 4.10, TG Therapeutics, Inc. holds $4.10 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 88/100.

Cash Flow

TG Therapeutics, Inc.'s operations used $24.8M of cash, and capex of $214K added to the outflow, for a free cash flow shortfall of $25.0M. This results in a cash flow score of 13/100.

Returns

TG Therapeutics, Inc.'s ROE of 69.0% shows moderate profitability relative to equity, earning a score of 56/100. This is up from 10.5% the prior year.

Altman Z-Score Safe

12.32

TG Therapeutics, Inc. scores 12.32, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($8.5B) relative to total liabilities ($415.2M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

4/9

TG Therapeutics, Inc. passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

$0.06used

For every $1 of reported earnings, TG Therapeutics, Inc. used $0.06 of operating cash (-$24.8M OCF vs $447.2M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.

Interest Coverage Adequate

4.61x

TG Therapeutics, Inc. earns $4.61 in operating income for every $1 of interest expense ($123.3M vs $26.7M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$240.3M

YoY+70.3%

QoQ+17.3%

5Y CAGR+174.4%

TG Therapeutics, Inc. generated $240.3M in revenue in Q2 2026. This represents an increase of 70.3% from the same quarter a year earlier. Against the prior quarter it is up 17.3%.

EBITDA

$21.7M

YoY-37.7%

QoQ-37.6%

TG Therapeutics, Inc.'s EBITDA was $21.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 37.7% from the same quarter a year earlier. Against the prior quarter it is down 37.6%.

Net Income

$7.8M

YoY-72.4%

QoQ-60.7%

TG Therapeutics, Inc. reported $7.8M in net income in Q2 2026. This represents a decrease of 72.4% from the same quarter a year earlier. Against the prior quarter it is down 60.7%.

EPS (Diluted)

$0.05

YoY-70.6%

QoQ-58.3%

TG Therapeutics, Inc. earned $0.05 per diluted share (EPS) in Q2 2026. This represents a decrease of 70.6% from the same quarter a year earlier. Against the prior quarter it is down 58.3%.

Cash & Balance Sheet

Free Cash Flow

$39.0M

YoY+427.0%

QoQ+317.2%

TG Therapeutics, Inc. generated $39.0M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 427.0% from the same quarter a year earlier. Against the prior quarter it is up 317.2%.

Cash & Debt

$482.6M

YoY+273.7%

QoQ+9.1%

5Y CAGR+3.7%

10Y CAGR+32.7%

TG Therapeutics, Inc. held $482.6M in cash against $745.4M in long-term debt as of Q2 2026.

Shares Outstanding

153M

YoY-3.5%

QoQ0.0%

5Y CAGR+1.4%

10Y CAGR+10.9%

TG Therapeutics, Inc. had 153M shares outstanding in Q2 2026. This represents a decrease of 3.5% from the same quarter a year earlier. It is unchanged from the prior quarter.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

82.9%

YoY-3.7pp

QoQ-0.8pp

TG Therapeutics, Inc.'s gross margin was 82.9% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 3.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.8 percentage points.

Operating Margin

9.0%

YoY-15.7pp

QoQ-8.0pp

TG Therapeutics, Inc.'s operating margin was 9.0% in Q2 2026, reflecting core business profitability. This is down 15.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 8.0 percentage points.

Net Margin

3.2%

YoY-16.7pp

QoQ-6.4pp

TG Therapeutics, Inc.'s net profit margin was 3.2% in Q2 2026, showing the share of revenue converted to profit. This is down 16.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 6.4 percentage points.

Return on Equity

1.3%

YoY-8.9pp

QoQ-2.1pp

5Y change+21.8pp

TG Therapeutics, Inc.'s ROE was 1.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 8.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.1 percentage points.

Capital Allocation

R&D Spending

$95.3M

YoY+200.0%

QoQ+97.0%

5Y CAGR+16.3%

TG Therapeutics, Inc. invested $95.3M in research and development in Q2 2026. This represents an increase of 200.0% from the same quarter a year earlier. Against the prior quarter it is up 97.0%.

Share Buybacks

YoY-100.0%

QoQ-100.0%

TG Therapeutics, Inc. repurchased no shares in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.

Capital Expenditures

$293K

YoY+597.6%

QoQ+474.5%

TG Therapeutics, Inc. invested $293K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 597.6% from the same quarter a year earlier. Against the prior quarter it is up 474.5%.

TGTX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TGTX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$799.5M	$616.3M+87.3%	$329.0M+40.8%	$233.7M+8290.0%	$2.8M-58.4%	$6.7M+4300.7%	$152K0.0%	$152K0.0%	$152K0.0%	$152K0.0%	$152K	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	$140.9M	$100.7M+161.7%	$38.5M+172.4%	$14.1M+5232.5%	$265K-66.5%	$790K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	$658.6M	$515.6M+77.5%	$290.5M+32.3%	$219.5M+8611.5%	$2.5M-57.3%	$5.9M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$225.8M	$160.2M+69.9%	$94.3M+23.8%	$76.2M-39.2%	$125.4M-43.7%	$222.6M+34.2%	$165.9M+7.6%	$154.2M-3.3%	$159.4M+55.5%	$102.5M+48.1%	$69.2M+45.1%	$47.7M+19.0%	$40.1M+193.4%	$13.7M-35.0%	$21.0M+6325.0%	$327K
SG&A Expenses	$296.5M	$232.0M+50.4%	$154.3M+25.7%	$122.7M+28.5%	$95.5M-25.5%	$128.1M+18.8%	$107.8M+617.7%	$15.0M-0.9%	$15.2M-7.2%	$16.3M+65.1%	$9.9M-36.7%	$15.6M-1.0%	$15.8M+137.1%	$6.7M+39.2%	$4.8M+762.0%	$555K
Operating Income	$136.3M	$123.3M+194.1%	$41.9M+103.2%	$20.6M+109.5%	-$218.3M+36.7%	-$344.8M-26.0%	-$273.6M-61.8%	-$169.1M+3.1%	-$174.4M-46.9%	-$118.7M-50.3%	-$79.0M-25.0%	-$63.2M-13.4%	-$55.7M-142.6%	-$23.0M+14.6%	-$26.9M-2949.4%	-$882K
EBITDA	N/A	$123.4M+193.8%	$42.0M+101.5%	$20.8M+109.6%	-$218.0M+36.7%	-$344.5M-26.1%	-$273.2M-61.9%	-$168.8M+3.2%	-$174.3M-46.9%	-$118.6M-50.3%	-$78.9M-24.9%	-$63.2M-13.4%	-$55.7M-142.6%	-$23.0M+14.6%	-$26.9M-2949.4%	-$882K
Interest Expense	$37.5M	$26.7M+11.2%	$24.0M+90.5%	$12.6M+23.8%	$10.2M+80.8%	$5.6M-10.9%	$6.3M+19.7%	$5.3M+502.9%	$877K+3.8%	$845K	N/A	$973K+4.5%	$931K-2.3%	$953K+5.2%	$906K+12662.4%	$7K
Income Tax	-$339.9M	-$339.8M-15468.1%	$2.2M+466.9%	$390K	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$300K	$0
Net Income	$441.5M	$447.2M+1811.1%	$23.4M+84.3%	$12.7M+106.4%	-$198.3M+43.0%	-$348.1M-24.6%	-$279.4M-61.6%	-$172.9M+0.4%	-$173.5M-46.4%	-$118.5M-51.4%	-$78.3M-24.3%	-$62.9M-12.8%	-$55.8M-172.4%	-$20.5M-13.3%	-$18.1M-2018.5%	-$853K
EPS (Basic)	N/A	$3.10+1837.5%	$0.16+77.8%	$0.09+105.5%	-$1.65+37.3%	-$2.63-8.7%	-$2.42	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	$2.75	$2.77+1746.7%	$0.15+66.7%	$0.09+105.5%	-$1.65+37.3%	-$2.63-8.7%	-$2.42	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	161M+0.7%	160M+8.0%	149M+9.7%	135M+2.4%	132M+14.6%	115M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$240.3M+70.3%	$204.9M+69.6%	$192.6M+78.0%	$161.7M+92.8%	$141.1M+92.1%	$120.9M+90.4%	$108.2M+146.0%	$83.9M-49.4%
Cost of Revenue	$41.2M+117.5%	$33.5M+115.6%	$38.1M+147.7%	$28.1M+200.7%	$18.9M+128.1%	$15.5M+185.6%	$15.4M+96.1%	$9.3M+166.2%
Gross Profit	$199.1M+62.9%	$171.4M+62.8%	$154.4M+66.4%	$133.6M+79.3%	$122.2M+87.5%	$105.3M+81.5%	$92.8M+156.9%	$74.5M-54.1%
R&D Expenses	$95.3M+200.0%	$48.4M+4.4%	$41.2M+72.5%	$40.9M+103.0%	$31.8M+81.0%	$46.4M+41.7%	$23.9M+36.8%	$20.1M+36.5%
SG&A Expenses	$82.1M+47.8%	$88.2M+75.3%	$62.7M+61.0%	$63.4M+51.0%	$55.6M+43.3%	$50.3M+45.5%	$39.0M+25.1%	$42.0M+28.1%
Operating Income	$21.7M-37.8%	$34.8M+303.6%	$50.5M+68.6%	$29.4M+136.2%	$34.8M+295.2%	$8.6M+193.0%	$29.9M+339.9%	$12.4M-89.2%
EBITDA	$21.7M-37.7%	$34.8M+303.6%	$50.5M+68.6%	$29.4M+136.1%	$34.9M+294.5%	$8.6M+193.4%	$30.0M+340.7%	$12.4M-89.2%
Interest Expense	$16.6M+146.8%	$7.7M+13.5%	$6.5M-5.7%	$6.7M-38.0%	$6.7M+68.9%	$6.8M+195.3%	$6.9M+185.1%	$10.8M+191.7%
Income Tax	$2.5M-10.2%	$586K+43.6%	$22.1M+939.4%	-$365.0M-94168.6%	$2.7M+933.2%	$408K+1306.9%	$2.1M	$388K
Net Income	$7.8M-72.4%	$19.8M+290.8%	$23.1M-1.2%	$390.9M+9974.6%	$28.2M+309.8%	$5.1M+147.3%	$23.3M+262.3%	$3.9M-96.6%
EPS (Basic)	$0.05-73.7%	$0.14+366.7%	$0.20+25.0%	$2.69+8866.7%	$0.19+280.0%	$0.03+142.9%	$0.16+260.0%	$0.03-96.3%
EPS (Diluted)	$0.05-70.6%	$0.12+300.0%	$0.150.0%	$2.43+12050.0%	$0.17+325.0%	$0.03+142.9%	$0.15+250.0%	$0.02-97.3%
Diluted Shares (Avg)	157M-3.2%	160M-1.7%	N/A	161M+0.2%	163M+2.0%	163M+11.3%	N/A	161M+3.1%

TGTX Balance Sheet

TGTX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$1.1B+84.1%	$577.7M+75.3%	$329.6M+70.3%	$193.6M-49.0%	$379.6M-39.3%	$625.6M+283.8%	$163.0M+95.0%	$83.6M-14.1%	$97.4M+77.8%	$54.8M-51.7%	$113.5M+30.8%	$86.7M+80.3%	$48.1M+118.0%	$22.1M+51.8%	$14.5M
Current Assets	$630.8M+11.4%	$566.4M+78.1%	$317.9M+88.9%	$168.3M-49.2%	$331.0M-45.9%	$611.7M+310.1%	$149.2M+88.7%	$79.0M-15.3%	$93.3M+83.5%	$50.9M-41.5%	$86.9M+1.9%	$85.2M+101.4%	$42.3M+129.0%	$18.5M+87.8%	$9.8M
Cash & Equivalents	$79.1M-56.0%	$179.9M+93.6%	$92.9M-9.2%	$102.3M-65.8%	$298.9M-46.0%	$553.4M+391.3%	$112.6M+168.5%	$42.0M-26.0%	$56.7M+126.6%	$25.0M-54.5%	$55.1M-1.2%	$55.7M+37.6%	$40.5M+146.0%	$16.5M+68.8%	$9.7M
Short-Term Investments	$62.8M-52.1%	$131.1M+5.2%	$124.6M+109.8%	$59.4M+274.0%	$15.9M-69.5%	$52.0M+87.0%	$27.8M+3.2%	$26.9M-3.8%	$28.0M+41.0%	$19.9M-10.4%	$22.2M-3.9%	$23.1M	$0	$0	$0
Inventory	$125.6M+13.7%	$110.5M+177.4%	$39.8M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$305.6M+136.6%	$129.2M+152.8%	$51.1M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$59.1M+7218.8%	$808K	$0-100.0%	$12.4M-65.1%	$35.5M	$0	$0	$0	$0	$0-100.0%	$25.0M	$0-100.0%	$4.9M	$0	$0
Goodwill	N/A	N/A	$799K0.0%	$799K0.0%	$799K0.0%	$799K0.0%	$799K0.0%	$799K0.0%	$799K0.0%	$799K0.0%	$799K0.0%	$799K0.0%	$799K0.0%	$799K0.0%	$799K
Total Liabilities	$415.2M+16.9%	$355.3M+110.1%	$169.1M+25.3%	$135.0M-5.3%	$142.5M+34.0%	$106.3M-14.6%	$124.4M+108.8%	$59.6M+96.1%	$30.4M+60.7%	$18.9M+58.9%	$11.9M+79.1%	$6.6M-17.5%	$8.1M+23.5%	$6.5M+33.1%	$4.9M
Current Liabilities	$153.8M+69.6%	$90.7M+68.8%	$53.7M+1.0%	$53.2M-18.6%	$65.4M-25.3%	$87.6M+3.7%	$84.4M+117.3%	$38.9M+39.0%	$28.0M+65.6%	$16.9M+60.3%	$10.5M+105.6%	$5.1M-18.9%	$6.3M+185.1%	$2.2M+38.0%	$1.6M
Non-Current Liabilities	$261.5M-1.2%	$264.6M+129.4%	$115.4M+41.1%	$81.8M+6.1%	$77.1M+311.4%	$18.7M-53.1%	$40.0M+92.8%	$20.7M+752.6%	$2.4M+19.4%	$2.0M+48.4%	$1.4M-10.0%	$1.5M-12.5%	$1.7M-59.6%	$4.3M+30.7%	$3.3M
Long-Term Debt	$245.6M+0.5%	$244.4M+144.1%	$100.1M+40.7%	$71.1M+6.5%	$66.8M+765.6%	$7.7M-73.4%	$29.0M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$648.0M+191.4%	$222.4M+38.5%	$160.5M+174.0%	$58.6M-75.3%	$237.2M-54.3%	$519.4M+1244.9%	$38.6M+60.7%	$24.0M-64.1%	$67.0M+86.8%	$35.9M-64.7%	$101.6M+26.8%	$80.1M+100.0%	$40.1M+157.6%	$15.6M+61.6%	$9.6M
Retained Earnings	-$1.1B+29.2%	-$1.5B+1.5%	-$1.6B-1.7%	-$1.5B-14.9%	-$1.3B-35.5%	-$980.6M-39.8%	-$701.2M-32.7%	-$528.3M-48.9%	-$354.9M-50.1%	-$236.4M-49.5%	-$158.1M-66.1%	-$95.2M-141.6%	-$39.4M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$1.6B+133.4%	$1.5B+132.8%	$1.1B+84.1%	$1.0B+74.9%	$702.6M+75.1%	$656.7M+75.9%	$577.7M+75.3%	$586.0M+77.0%
Current Assets	$1.1B+72.6%	$1.1B+68.7%	$630.8M+11.4%	$599.8M+4.5%	$664.0M+70.6%	$644.5M+78.7%	$566.4M+78.1%	$574.1M+79.9%
Cash & Equivalents	$482.6M+273.7%	$442.2M+234.7%	$79.1M-56.0%	$74.1M-62.2%	$129.1M+55.7%	$132.1M+75.1%	$179.9M+93.6%	$195.8M+29.8%
Short-Term Investments	$69.7M-43.2%	$72.2M-49.9%	$62.8M-52.1%	$57.5M-60.4%	$122.7M-8.6%	$144.1M+7.3%	$131.1M+5.2%	$145.2M+85.6%
Inventory	$148.0M-4.7%	$129.0M-18.2%	$125.6M+13.7%	$147.0M+73.6%	$155.2M+91.0%	$157.8M+103.0%	$110.5M+177.4%	$84.7M+152.3%
Accounts Receivable	$401.6M+73.5%	$392.0M+106.2%	$305.6M+136.6%	$265.4M+129.3%	$231.5M+176.9%	$190.1M+192.6%	$129.2M+152.8%	$115.7M
Long-Term Investments	$64.4M+125.1%	$61.5M+3127.0%	$59.1M+7218.8%	$48.8M+4234.0%	$28.6M+2919.0%	$1.9M+44.5%	$808K	$1.1M
Total Liabilities	$1.0B+143.0%	$945.7M+125.5%	$415.2M+16.9%	$417.8M+6.1%	$426.2M+90.6%	$419.4M+96.7%	$355.3M+110.1%	$393.9M+136.8%
Current Liabilities	$268.5M+56.2%	$187.1M+16.8%	$153.8M+69.6%	$156.8M+25.3%	$171.9M+58.2%	$160.2M+60.7%	$90.7M+68.8%	$125.1M+116.9%
Non-Current Liabilities	$767.1M+201.6%	$758.6M+192.7%	$261.5M-1.2%	$261.0M-2.9%	$254.3M+121.2%	$259.2M+128.3%	$264.6M+129.4%	$268.7M+147.4%
Long-Term Debt	$745.4M+204.2%	$745.1M+204.5%	$245.6M+0.5%	$245.3M+0.5%	$245.0M+139.0%	$244.7M+141.5%	$244.4M+144.1%	$244.2M+146.9%
Total Equity	$604.1M+118.5%	$583.1M+145.7%	$648.0M+191.4%	$607.2M+216.0%	$276.4M+55.7%	$237.3M+48.2%	$222.4M+38.5%	$192.2M+16.6%
Retained Earnings	-$1.1B+29.5%	-$1.1B+30.3%	-$1.1B+29.2%	-$1.1B+28.8%	-$1.5B+3.9%	-$1.5B+0.1%	-$1.5B+1.5%	-$1.6B-3.5%

Not reported in any period shown, so not listed: Goodwill.

TGTX Cash Flow Statement

TGTX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$17.9M	-$24.8M+38.9%	-$40.5M-29.0%	-$31.4M+82.2%	-$176.2M+40.4%	-$295.6M-37.8%	-$214.5M-61.5%	-$132.8M-3.0%	-$128.9M-37.5%	-$93.8M-52.2%	-$61.6M-37.8%	-$44.7M-27.5%	-$35.1M-226.5%	-$10.7M-107.0%	-$5.2M-5892.3%	-$87K
Depreciation & Amortization	N/A	$59K-13.2%	$68K-67.8%	$211K-30.4%	$303K+7.4%	$282K-24.6%	$374K+32.6%	$282K+220.5%	$88K+7.3%	$82K+30.2%	$63K+307.7%	$15K+293.1%	$4K+248.8%	$1K+379.6%	$235	$0
Stock-Based Compensation	N/A	$64.7M+52.0%	$42.5M+12.1%	$37.9M-15.1%	$44.7M-27.1%	$61.3M-23.7%	$80.3M+608.3%	$11.3M-12.0%	$12.9M-19.0%	$15.9M+112.0%	$7.5M-52.2%	$15.7M-25.6%	$21.1M+305.6%	$5.2M+52.0%	$3.4M+3856.6%	$86K
Capital Expenditures	$491K	$214K+375.6%	$45K	$0-100.0%	$14K-96.5%	$401K+12.3%	$357K+172.5%	$131K+45.6%	$90K+4400.0%	$2K-99.4%	$344K+714.8%	$42K+127.3%	$19K+226.9%	$6K+306.1%	$1K	$0
Free Cash Flow	$17.4M	-$25.0M+38.4%	-$40.6M-29.1%	-$31.4M+82.2%	-$176.2M+40.5%	-$296.0M-37.8%	-$214.9M-61.6%	-$132.9M-3.0%	-$129.0M-37.6%	-$93.8M-51.4%	-$61.9M-38.4%	-$44.7M-27.5%	-$35.1M-226.5%	-$10.7M-107.1%	-$5.2M-5893.9%	-$87K
Investing Cash Flow	$21.9M	$13.8M+1431.9%	-$1.0M+98.0%	-$50.7M-153.1%	-$20.0M-5928.0%	-$332K+98.6%	-$24.5M-3313.6%	-$718K-160.8%	$1.2M+114.4%	-$8.2M	N/A	N/A	N/A	N/A	-$1K-113.5%	$10K
Financing Cash Flow	$313.7M	-$89.7M-169.8%	$128.5M+76.8%	$72.7M+18694.6%	-$391K-100.9%	$41.4M-93.9%	$679.8M+232.9%	$204.2M+79.7%	$113.6M-15.0%	$133.7M	N/A	N/A	N/A	N/A	$11.9M+21.1%	$9.8M
Share Buybacks	$178.2M	$91.2M+941.6%	$8.8M	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$150K+77.2%	$85K	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$39.3M+428.0%	-$17.9M+37.7%	$19.7M+176.7%	-$23.2M-89.7%	$7.4M+34.3%	-$28.7M-249.9%	-$25.6M-94.1%	-$12.2M-114.6%
Depreciation & Amortization	$53K+307.7%	$32K+300.0%	$21K+133.3%	$17K+54.5%	$13K-31.6%	$8K-72.4%	$9K-76.3%	$11K-84.9%
Stock-Based Compensation	N/A	$19.9M+33.2%	N/A	N/A	$16.4M+72.6%	$15.0M+60.3%	N/A	$11.8M+28.3%
Capital Expenditures	$293K+597.6%	$51K+104.0%	$67K+219.0%	$80K+233.3%	$42K	$25K	$21K	$24K
Free Cash Flow	$39.0M+427.0%	-$17.9M+37.6%	$19.6M+176.4%	-$23.2M-90.0%	$7.4M+33.6%	-$28.7M-250.2%	-$25.7M-94.3%	-$12.2M
Investing Cash Flow	$1.0M+125.8%	-$9.9M+23.7%	-$15.6M-199.0%	$46.4M+596.7%	-$4.0M-326.2%	-$12.9M-39.8%	$15.8M+135.3%	-$9.3M+69.1%
Financing Cash Flow	$85K+101.3%	$390.8M+6504.9%	$1.1M+117.4%	-$78.2M-158.2%	-$6.4M-4872.6%	-$6.1M-61120.0%	-$6.1M-607100.0%	$134.5M+31836.8%
Share Buybacks	$0-100.0%	$100.0M+1533.1%	$0-100.0%	$78.2M+3540.9%	$6.9M	$6.1M	$6.6M	$2.1M

Not reported in any period shown, so not listed: Dividends Paid.

TGTX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TGTX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	83.7%-4.6pp	88.3%-5.6pp	94.0%+3.5pp	90.5%+2.3pp	88.2%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	20.0%+7.3pp	12.7%+3.9pp	8.8%	-7839.0%	-5154.3%	-179996.0%	-111220.4%	-114736.8%	-78100.0%	-51953.3%	N/A	N/A	N/A	N/A	N/A
Net Margin	72.6%+65.5pp	7.1%+1.7pp	5.4%	-7120.3%	-5204.1%	-183803.3%	-113730.9%	-114132.9%	-77944.7%	-51482.2%	N/A	N/A	N/A	N/A	N/A
Return on Equity	69.0%+58.5pp	10.5%+2.6pp	7.9%+346.4pp	-338.5%-191.7pp	-146.8%-93.0pp	-53.8%+393.9pp	-447.7%+274.1pp	-721.8%-544.9pp	-176.8%+41.3pp	-218.2%-156.2pp	-62.0%+7.7pp	-69.6%-18.5pp	-51.1%+65.1pp	-116.2%-107.4pp	-8.9%
Return on Assets	42.1%+38.0pp	4.0%+0.2pp	3.9%+106.3pp	-102.4%-10.7pp	-91.7%-47.0pp	-44.7%+61.4pp	-106.0%+101.4pp	-207.5%-85.8pp	-121.7%+21.2pp	-142.9%-87.4pp	-55.5%+8.8pp	-64.3%-21.7pp	-42.6%+39.3pp	-81.9%-76.0pp	-5.9%
Current Ratio	4.10-2.1x	6.25+0.3x	5.92+2.8x	3.16-1.9x	5.06-1.9x	6.99+5.2x	1.77-0.3x	2.03-1.3x	3.34+0.3x	3.01-5.2x	8.25-8.4x	16.64+9.9x	6.70-1.6x	8.34+2.2x	6.12
Debt-to-Equity	0.38-0.7x	1.10+0.5x	0.62-0.6x	1.21+0.9x	0.28+0.3x	0.01-0.7x	0.75+0.8x	0.00-0.5x	0.45-0.1x	0.53+0.4x	0.120.0x	0.08-0.1x	0.20-0.2x	0.42-0.1x	0.51
Asset Turnover	0.580.0x	0.57-0.1x	0.71+0.7x	0.010.0x	0.020.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.00	N/A	N/A	N/A	N/A	N/A
FCF Margin	-4.0%+8.3pp	-12.3%+1.1pp	-13.4%	-6326.2%	-4425.7%	-141357.9%	-87458.6%	-84878.3%	-61685.5%	-40744.1%	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	82.9%-3.7pp	83.7%-3.5pp	80.2%-5.6pp	82.6%-6.2pp	86.6%-2.1pp	87.1%-4.3pp	85.8%+3.6pp	88.9%-9.0pp
Operating Margin	9.0%-15.7pp	17.0%+9.8pp	26.2%-1.5pp	18.2%+3.3pp	24.7%+12.7pp	7.1%+21.7pp	27.7%+56.1pp	14.8%-54.4pp
Net Margin	3.2%-16.7pp	9.7%+5.5pp	12.0%-9.6pp	241.7%	20.0%+10.6pp	4.2%+21.1pp	21.6%+54.3pp	4.6%-64.1pp
Return on Equity	1.3%-8.9pp	3.4%+1.3pp	3.6%-6.9pp	64.4%+62.4pp	10.2%+6.3pp	2.1%+8.8pp	10.5%+19.5pp	2.0%-67.1pp
Return on Assets	0.5%-3.5pp	1.3%+0.5pp	2.2%-1.9pp	38.1%+37.5pp	4.0%+2.3pp	0.8%+3.6pp	4.0%+8.4pp	0.7%-33.8pp
Current Ratio	4.27+0.4x	5.81+1.8x	4.10-2.1x	3.82-0.8x	3.86+0.3x	4.02+0.4x	6.25+0.3x	4.59-0.9x
Debt-to-Equity	1.23+0.3x	1.28+0.2x	0.38-0.7x	0.40-0.9x	0.89+0.3x	1.03+0.4x	1.10+0.5x	1.27+0.7x
Asset Turnover	0.15-0.1x	0.130.0x	0.180.0x	0.160.0x	0.200.0x	0.180.0x	0.19+0.1x	0.14-0.4x
FCF Margin	16.2%+11.0pp	-8.8%+15.0pp	10.2%+33.9pp	-14.4%+0.2pp	5.2%-2.3pp	-23.8%-10.9pp	-23.7%+6.3pp	-14.6%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
TG Therapeutics, Inc. TGTX	FY2025	$616.3M	$447.2M	72.6%	$8.5B	60/100
Merus N.V. MRUS	FY2024	$36.1M	-$215.3M	N/A	$6.8B	59/100
CRISPR Therapeutics AG CRSP	FY2025	$3.5M	-$581.6M	N/A	$5.2B	53/100
PTC Therapeutics, Inc. PTCT	FY2025	$1.7B	$683.0M	39.5%	$5.4B	53/100
Legend Biotech Corporation LEGN	FY2025	$1.0B	-$296.8M	-28.8%	$3.6B	41/100

Where TG Therapeutics, Inc. Ranks

Frequently Asked Questions

What is TG Therapeutics, Inc.'s annual revenue?

TG Therapeutics, Inc. (TGTX) reported $616.3M in total revenue for fiscal year 2025. This represents a 87.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is TG Therapeutics, Inc.'s revenue growing?

TG Therapeutics, Inc. (TGTX) revenue grew by 87.3% year-over-year, from $329.0M to $616.3M in fiscal year 2025.

Is TG Therapeutics, Inc. profitable?

Yes, TG Therapeutics, Inc. (TGTX) reported a net income of $447.2M in fiscal year 2025, with a net profit margin of 72.6%.

What is TG Therapeutics, Inc.'s EBITDA?

TG Therapeutics, Inc. (TGTX) had EBITDA of $123.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does TG Therapeutics, Inc. have?

As of fiscal year 2025, TG Therapeutics, Inc. (TGTX) had $79.1M in cash and equivalents against $245.6M in long-term debt.

What is TG Therapeutics, Inc.'s gross margin?

TG Therapeutics, Inc. (TGTX) had a gross margin of 83.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is TG Therapeutics, Inc.'s operating margin?

TG Therapeutics, Inc. (TGTX) had an operating margin of 20.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is TG Therapeutics, Inc.'s net profit margin?

TG Therapeutics, Inc. (TGTX) had a net profit margin of 72.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is TG Therapeutics, Inc.'s return on equity (ROE)?

TG Therapeutics, Inc. (TGTX) has a return on equity of 69.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is TG Therapeutics, Inc.'s free cash flow?

TG Therapeutics, Inc. (TGTX) recorded an outflow of $25.0M in free cash flow during fiscal year 2025. This represents a 38.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is TG Therapeutics, Inc.'s operating cash flow?

TG Therapeutics, Inc. (TGTX) recorded an outflow of $24.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are TG Therapeutics, Inc.'s total assets?

TG Therapeutics, Inc. (TGTX) had $1.1B in total assets as of fiscal year 2025, including both current and long-term assets.

What are TG Therapeutics, Inc.'s capital expenditures?

TG Therapeutics, Inc. (TGTX) invested $214K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does TG Therapeutics, Inc. spend on research and development?

TG Therapeutics, Inc. (TGTX) invested $160.2M in research and development during fiscal year 2025.

Does TG Therapeutics, Inc. buy back shares?

Yes, TG Therapeutics, Inc. (TGTX) spent $91.2M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does TG Therapeutics, Inc. have outstanding?

TG Therapeutics, Inc. (TGTX) had 160M shares outstanding as of fiscal year 2025.

What is TG Therapeutics, Inc.'s current ratio?

TG Therapeutics, Inc. (TGTX) had a current ratio of 4.10 as of fiscal year 2025, which is generally considered healthy.

What is TG Therapeutics, Inc.'s debt-to-equity ratio?

TG Therapeutics, Inc. (TGTX) had a debt-to-equity ratio of 0.38 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is TG Therapeutics, Inc.'s return on assets (ROA)?

TG Therapeutics, Inc. (TGTX) had a return on assets of 42.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is TG Therapeutics, Inc.'s P/E ratio?

TG Therapeutics, Inc. (TGTX) trades at 19.2x earnings, its market capitalization divided by net income of $441.5M net income, trailing 12 months to June 30, 2026. The market capitalization is $8.5B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is TG Therapeutics, Inc.'s price-to-sales ratio?

TG Therapeutics, Inc. (TGTX) trades at 10.6x sales, its market capitalization divided by revenue of $799.5M revenue, trailing 12 months to June 30, 2026. The market capitalization is $8.5B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does TG Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, TG Therapeutics, Inc. (TGTX) held $201.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $24.8M over that year. Dividing the one by the other, the reported balance equals about 97 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is TG Therapeutics, Inc.'s Altman Z-Score?

TG Therapeutics, Inc. (TGTX) has an Altman Z-Score of 12.32, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is TG Therapeutics, Inc.'s Piotroski F-Score?

TG Therapeutics, Inc. (TGTX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are TG Therapeutics, Inc.'s earnings high quality?

For every $1 of reported earnings, TG Therapeutics, Inc. (TGTX) used $0.06 of operating cash (-$24.8M OCF vs $447.2M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can TG Therapeutics, Inc. cover its interest payments?

TG Therapeutics, Inc. (TGTX) has an interest coverage ratio of 4.61x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is TG Therapeutics, Inc.?

TG Therapeutics, Inc. (TGTX) scores 60 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.